ERBB2 and medulloblastoma: Given our data, advances in the understanding of CAR T cell therapies, and the recently published case report of one patient who safely received intraventricular IL13Rα2-targeted CAR T cells [43], intraventricular delivery of HER2-BBz-CAR T cells starting at a low-dose using careful dose-escalation without a systemic lymphodepleting regimen is a rational approach to translate this promising therapy to patients with relapsed medulloblastoma.